Screening for Anticancer Leads from Marine Organisms in a Mechanism-Based Drug Discovery Program

1994 ◽  
pp. 365-403 ◽  
Author(s):  
P. Crews ◽  
D. L. Slate ◽  
W. H. Gerwick ◽  
F. J. Schmitz ◽  
R. Schatzman ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Marine Organisms ◽  
Drug Discovery Program ◽  
Discovery Program

An Efficient Palladium-Catalyzed α-Arylation of Acetone Below its Boiling Point

Synlett ◽  
2020 ◽  
Vol 31 (15) ◽  
pp. 1532-1536
Author(s):  
Jeffery Richardson ◽  
Simon P. Mutton ◽  
Fionna M. Martin ◽  
Lesley Walton ◽  
Andrew J. Ledgard
Keyword(s):  
Drug Discovery ◽  
Boiling Point ◽  
Aryl Halide ◽  
Ambient Temperatures ◽  
Drug Discovery Program ◽  
Palladium Catalyzed ◽  
Discovery Program

The monoarylation of acetone is a powerful transformation, but is typically performed at temperatures significantly in excess of its boiling point. Conditions described for performing the reaction at ambient temperatures led to significant dehalogenation when applied to a complex aryl halide. We describe our attempts to overcome both issues in the context of our drug-discovery program.

INSIDE INDUSTRY

2013 ◽  
Vol 17 (08) ◽  
pp. 58-62
Keyword(s):  
Drug Discovery ◽  
Life Sciences ◽  
Regional Office ◽  
Drug Discovery Program ◽  
Discovery Program ◽  
Collaborative Drug Discovery ◽  
Future Leaders

GE Healthcare Life Sciences and Osaka University team up to develop future leaders of Japan's life sciences sector. Quintiles acquires Novella Clinical. Tim Reiner joins Mundipharma's regional office. Daiichi Sankyo to expand its collaborative drug discovery program to Germany, Switzerland, and Austria. Eurofins Panlabs strengthens drug discovery services with GE Healthcare's Cytiva™ Cardiomyocytes.

Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDS

Stem Cells ◽  
1994 ◽  
Vol 12 (1) ◽  
pp. 13-22 ◽  
Author(s):  
J. N. Weinstein ◽  
T. Myers ◽  
J. Buolamwini ◽  
K. Raghavan ◽  
W. Van Osdol ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Drug Discovery ◽  
Drug Discovery Program ◽  
Discovery Program ◽  
The U.S

scholarly journals Discovery of Bioactive Compounds by the UIC-ICBG Drug Discovery Program in the 18 Years Since 1998

Molecules ◽  
2016 ◽  
Vol 21 (11) ◽  
pp. 1448 ◽  
Author(s):  
Hong-Jie Zhang ◽  
Wan-Fei Li ◽  
Harry Fong ◽  
Djaja Soejarto
Keyword(s):  
Drug Discovery ◽  
Bioactive Compounds ◽  
Drug Discovery Program ◽  
Discovery Program

Preferred, Novel and Neglected Scaffolds: Natural Products in a Drug Discovery Program

Planta Medica ◽  
2009 ◽  
Vol 75 (09) ◽  
Author(s):  
M O'Neil-Johnson ◽  
R Williams ◽  
C Starks ◽  
JF Jin-Feng Hu ◽  
G Eldridge
Keyword(s):  
Natural Products ◽  
Drug Discovery ◽  
Drug Discovery Program ◽  
Discovery Program

Industry Watch

2004 ◽  
Vol 08 (09) ◽  
pp. 473-486
Keyword(s):  
Clinical Trial ◽  
Drug Discovery ◽  
Micro Rna ◽  
Care Hospital ◽  
Drug Discovery Program ◽  
Discovery Program

Australia’s Bioinitiative Program: Pharmaceuticals Partnerships Program. China’s OTC Market. Glenmark GRC-3886 Enters Clinical Trial. Angioplasty Market in India. AHSL Acquires US-based MBPO. Care Hospital and IICT Collaborates to Launch Indigenous Coated Stent. Singapore Supports Isis Pharma’s Micro-RNA Drug Discovery Program. Eisai Acquires Zonegran® Exclusive Market Rights.

WHO-TDR's Drug Discovery Program forNeglected Diseases

Planta Medica ◽  
2008 ◽  
Vol 74 (03) ◽  
Author(s):  
S Nwaka ◽  
B Ramirez ◽  
F Fakorede ◽  
R Ridley
Keyword(s):  
Drug Discovery ◽  
Drug Discovery Program ◽  
Discovery Program

Conclusion

2017 ◽  
Author(s):  
Murphy Halliburton
Keyword(s):  
Drug Discovery ◽  
Open Source ◽  
Health Impact ◽  
Drug Discovery Program ◽  
Discovery Program

The conclusion reiterates the problems with analyzing this new constellation of power and of predicting its outcomes. Certain effective provisions are highlighted such as Section 3d of India’s new Patents Act which maintains rigorous standards of inventiveness and efficacy, preventing the “evergreening” of patents and “me too” drugs that have been awarded patents elsewhere. The study ends with a brief comparison to similar patent struggles in Brazil and an assessment of programs that offer more equitable approaches to innovation and ownership such as the Health Impact Fund and the Open Source Drug Discovery program.

Sign in / Sign up

Export Citation Format

Share Document